Arcline Investment Management, a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, today announced the acquisition of Polypeptide Therapeutic Solutions S.L. from Columbus Venture Partners. PTS is a GMP-grade manufacturer of polyamino-acid based nanoparticle encapsulation technology for advanced drug delivery applications, including mRNA, DNA, cell therapies, gene therapies, biologics, vaccines, and small molecule therapies.
Arcline commented, “We believe that the success of nanoparticle delivery technologies in COVID-19 mRNA vaccines has permanently accelerated the funding, development, and adoption of these advanced drug delivery systems. PTS’ technology seeks to improve the efficiency, targeting, and safety profile of delivery systems for novel therapeutics, bringing urgently needed treatments to patients across multiple disease areas. We are excited to invest in PTS’ continued growth through the expansion of its GMP production and its technology portfolio.”
Jose Vicente Pons Andreu, CEO of PTS, added, “Arcline is the right partner for us at a critical time when we must invest to meet our customers’ needs for scale in GMP production. They quickly saw the potential for our PAA technology platform to enable safer and more precise drug delivery. We look forward to working with them to expand our manufacturing footprint, accelerate our business development efforts, and bring new technologies to commercial scale.”
Damiá Tormo, general partner at Columbus, added, “We are very pleased with the acquisition of PTS by Arcline. We have found in Arcline the right partner that will enable PTS to scale up and leverage its technology in Europe and North America.”